Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

AstraZeneca’s Tagrisso to cost $12,750 for a month’s supply

Written by: | no-reply@reuters.com | Dated: Tuesday, November 17th, 2015

 

A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer’s Xalkori and Novartis’ Zykadia.

AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group’s growing oncology portfolio.

Its prospects received a boost on Monday when a rival drug from Clovis Oncology hit a snag, with U.S. health regulators asking for more data and Clovis reporting lower-than-expected confirmed response rates.

 

(Reporting by Ben Hirschler; editing by Jason Neely)

Source: Reuters Health

http://www.reuters.com/article/2015/11/17/us-astrazeneca-cancer-tagrisso-idUSKCN0T61J420151117

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom